The Most Trusted Name in Securities Class Action Law

Over $400 million recovered for investors in the last 2 years

Ampio Pharmaceuticals, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business

Read More

Blueprint Medicines Corporation

On August 17, 2022, before trading hours, Blueprint Medicines announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib)

Read More

Sinovac Biotech Ltd.

According to the lawsuit, defendants’ intentionally false statements and omissions concerning the true nature of 1Globe, a family investment office that is owned and controlled

Read More

Co-Diagnostics, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Co-Diagnostics was experiencing a significant falloff

Read More

Uber Technologies, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Uber had defective disclosure controls and

Read More

MINISO Group Holding Limited

According to the lawsuit,  the Registration Statement featured false and/or misleading statements and/or failed to disclose that: defendants and other undisclosed related parties owned and

Read More

Olo Inc.

On February 12, 2020, Olo issued a press release announcing “its partnership with Subway(R) restaurants to integrate digital orders directly into the restaurant’s point of

Read More

Coinbase Global, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Coinbase custodially held crypto assets on

Read More

LifeStance Health Group, Inc.

According to the lawsuit, the IPO Registration Statement featured false and/or misleading statements and/or failed to disclose that: the number of virtual visits clients were

Read More

Ampio Pharmaceuticals, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business

Read More

Blueprint Medicines Corporation

On August 17, 2022, before trading hours, Blueprint Medicines announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib)

Read More

Sinovac Biotech Ltd.

According to the lawsuit, defendants’ intentionally false statements and omissions concerning the true nature of 1Globe, a family investment office that is owned and controlled

Read More

Co-Diagnostics, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Co-Diagnostics was experiencing a significant falloff

Read More

Uber Technologies, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Uber had defective disclosure controls and

Read More

MINISO Group Holding Limited

According to the lawsuit,  the Registration Statement featured false and/or misleading statements and/or failed to disclose that: defendants and other undisclosed related parties owned and

Read More

Olo Inc.

On February 12, 2020, Olo issued a press release announcing “its partnership with Subway(R) restaurants to integrate digital orders directly into the restaurant’s point of

Read More

Coinbase Global, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Coinbase custodially held crypto assets on

Read More

LifeStance Health Group, Inc.

According to the lawsuit, the IPO Registration Statement featured false and/or misleading statements and/or failed to disclose that: the number of virtual visits clients were

Read More

Centessa Pharmaceuticals plc

On or around May 27, 2021, Centessa Pharmaceuticals conducted its initial public offering (“IPO”), selling 16.5 American depositary shares (“ADSs”) priced at $20.00 per share.

Read More

Kiromic BioPharma, Inc.

According to the lawsuit, the IPO documents failed to disclose that the Food and Drug Administration (“FDA”) had, prior to the filing of the IPO

Read More

Hyzon Motors Inc.

On August 4, 2022, after market hours, Hyzon Motors filed with the SEC a current report on Form 8-K which announced, in part, that: (1)

Read More

Avaya Holdings Corp.

On August 9, 2022, The Wall Street Journal published an article entitled “Avaya Taps Legal, Financial Advisers to Look at Debt Options” and also published another article

Read More

TuSimple Holdings Inc.

In April 2022, TuSimple conducted its initial public offering (IPO), selling approximately 33.78 million shares priced at $40.00 per share. Then on August 1, 2022,

Read More

Our Mission

The Rosen Law Firm, P.A. is dedicated to recovering damages for shareholders victimized by corporate fraud and other misconduct. Our attorneys have a wealth of knowledge and experience handling complex financial litigation and winning significant victories and settlements for our clients. By focusing exclusively on securities class actions and derivative litigation, we have risen to the forefront of plaintiffs’ firms and have recovered damages totaling hundreds of millions of dollars for our clients. Our mission is to protect shareholders rights.

In the News

FAQ

Class actions are lawsuits where one or more investors serve as the representative plaintiffs on behalf of a large group of investors that each purchased the same securities and suffered losses as a result of the same false statements or misconduct.  Class actions allow a court to decide the claims of many investors in a single lawsuit. This promotes efficiency, economy, and extends justice to investors whose claims are not large enough to merit an individual lawsuit.

This is the time period during which investors purchased securities in the company that is the subject of the class action.  Typically, the false statements or fraud begin on the first day of the class period and the full truth about the false statements or fraud is revealed on the last day of the class period.

A lead plaintiff is an investor that wishes to serve as a representative plaintiff in the class action on behalf of all the other investors that purchased securities during the Class Period.

The Lead Plaintiff’s role is to oversee the litigation with the assistance and advice of the class’s attorneys. Both the Lead Plaintiff and the class’s attorneys must direct the litigation for the benefit of the class foremost. Ultimately, it is the job of the Lead Plaintiff to decide what is a fair settlement amount for the Class and to approve any settlement offer.

Lead Counsel are the Class’s attorneys.  The Lead Plaintiff selects the Lead Counsel.  Lead Counsel should have extensive experience prosecuting securities class actions if they are to effectively represent investors in a securities class action. 

If the amount of your losses in the investment are significant to you, being a lead plaintiff allows you to be involved in the case and oversee important decisions in the litigation, particularly the amount of any settlement for investors.

Class action lawsuits often are filed when it would be impractical or prohibitively expensive for each person who was harmed to file an individual lawsuit, and they enable small shareholders or consumers to seek recovery from large corporations possessing much greater legal and financial resources. Generally, securities class actions are filed in the Federal District Courts and allege that the defendant(s) violated the Securities Act of 1933 and/or the anti-fraud provisions of the Securities Exchange Act of 1934. The typical class action takes at least 2-3 years to litigate, although the actual time it takes to resolve a case varies, depending on the complexity of the case, the issues involved, and other factors.

You can complete the online certification form on our website or at your request, we will email you a form to complete and you can send it back to us.

You do not pay any legal fees, costs or expenses. The Court will award the Lead Counsel any legal fees, costs or expenses from the money they recover for the class. If Lead Counsel doesn’t recover any money for the class, Lead Counsel doesn’t get paid any legal fees, costs or expenses.

Our Offices

New York

275 Madison Avenue,

40th Floor
New York, NY 10016
T: 212.686.1060
F: 212.202.3827

Los Angeles

355 South Grand Avenue, Suite 2450
Los Angeles, CA 90071
T: 213.785.2610
F: 213.226.4684

Philadelphia Metro

101 Greenwood Avenue,

Suite 440
Jenkintown, PA 19046
T: 215.600.2817

F: 212.202.3827

New Jersey

One Gateway Center,

Suite 2600
Newark, NJ 07102
T: 973.313.1887
F: 973.833.0399

Get a Free Consultation

Email us at info@rosenlegal.com 

The Rosen Law Firm is dedicated exclusively to recovering investment losses for investors in companies that have misrepresented material aspects of their business or whose officers and directors have breached their fiduciary duties to shareholders.

Scroll to Top